Fig. 3. Doxorubicin induces immune cell recruitment to the TME.

a A graph showing the percentages of T cells (CD3⁺) in the bone marrow of leukemia-bearing mice pre- and post-doxorubicin (DOX) treatment. *p = 0.0142, ****p < 0.0001. b Graph showing the percentages of cytotoxic T cells (CD3⁺–CD8⁺) as in (a). **p = 0.0099, ****p < 0.0001. c Graph showing the percentages of helper T cells (CD3⁺–CD4⁺) as in (a). **p = 0.0044, ****p < 0.0001. d Graph showing the percentages of a subset of T cells (CD3⁺–CD4⁺–CD25⁺) as in (a). n = 7 for WT-untreated, n = 8 for WT-D2 post-doxorubicin, n = 7 for IL-6 KO-untreated, n = 8 for IL-6 KO-D2 post-doxorubicin mice. Data from 3 independent experiments are shown. **p = 0.0059 between IL-6 KO samples, **p = 0.005 between treated WT and IL-6 KO samples. e Graph showing the percentages of dendritic cells (CD11c⁺–MHC-II⁺) as in (a). *p = 0.019. f Graph showing the percentages of neutrophils (F480⁻–CD11b⁺–Gr-1⁺) as in (a). *p = 0.0189, **p = 0.0029. g Graph showing the percentages of myeloid-derived suppressor cells/monocytes (CD11b⁺–Gr-1⁺) as in (a). h A graph showing mCherry⁺ B-ALL percentages in the bone marrow of leukemia-bearing mice pre- and post-doxorubicin treatment. All data were quantified by flow cytometry. Data are represented as a percent of DAPI-negative (live), mCherry-negative (non-leukemic) cells for immune populations. Data for all panels are represented as mean ± SEM. n = 7 for WT-untreated, n = 11 for WT-D2 post-doxorubicin, n = 7 for IL-6 KO-untreated, n = 10 for IL-6 KO-D2 post-doxorubicin mice, and data from 4 independent experiments are shown; applies for all panels unless otherwise noted. Analyzed by two-tailed Student t-test. There were no significant statistical comparisons between ‘untreated’ and ‘DOX treated’ samples of different genetic backgrounds, unless shown. D2 = Day 2. Source data are provided as a ‘Source data’ file.